A radioimmunoassay (RIA) for the determination of human group-II phospholipase A(2) (M-PLA(2)) has been developed. M-PLA(2) was purified from human spleen. Monoclonal antibody (IgG) was prepared by fusion of splenic cells from immunized mice with M-PLA(2) and the mouse myeloma cell line NS-1. The RIA was carried out by a single antibody method. The assay is sensitive (0.78 μg/1), reproducible and specific. In healthy individuals,the serum M-PLA2 concentration ranges from 1.4 to 4.2 μg/l, the average being 2.2± 0.1 μg/1 (mean ± SE). Using the RIA, we found increased serum M-PLA(2) in patients with various infections and malignant tumors. We also showed the postoperative transient elevation of serum M-PLA(2) in cases without any infectious complications. The elevation was independent of the surgical procedure or site. The maximum serum M-PLA(2) level was seen on the 2nd to 4th postoperative day. In these patients, the serum M-PLA(2) and C-reactive protein levels were significantly correlated. The present study indicated that serum M-PLA(2)is an acute phase reactant.

Keywords:
Phospholipase A2, group-11, Radioimmunoassay, Acute phase reactant
This content is only available via PDF.
1991
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.